Kowa And Daiichi Sankyo Sales Agreement For Livalo And Olmetec To End June 2013
This article was originally published in PharmAsia News
Executive Summary
Kowa and Daiichi Sankyo will terminate a sales agreement concerning Livalo (pitavastatin) for hyperlipidemia and Olmetec (olmesartan medoxomil) for hypertension June 30, the companies announced April 5.